In response to the phase I/II clinical trial for mobocertinib, where it displayed an ORR of 28%, mobocertinib was approved by the U.S. Food and Drug Administration (FDA) for patients with NSCLC harboring EGFR exon20ins mutation on Sep 15, 2021.46 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.